跳至主要内容
临床试验/NCT02796079
NCT02796079Unknown1 期

A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications

Jie Shen1 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2015年1月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
发起方
入组人数
240
试验地点
1
主要终点
Area of diabetic foot ulcers

研究概览

简要总结

Stem cell therapy has been a new and effective therapy in recent years for diabetic foot.This study intends to establish an optimal clinical research program, and attempts to break the technical bottleneck in the stem cell therapy for treating diabetes related vascular complications.

详细描述

Diabetic foot is one of the most serious chronic complications of diabetic patients, and still lacking effective treatments.

Stem cell therapy has been a new and effective therapy in recent years for diabetic foot. Combined with the previous studies of our research group, this study intends to transform part of the results of this research, establish an optimal clinical research program, and attempts to break the technical bottleneck in the stem cell therapy for treating diabetes related vascular complications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetes mellitus Type 2 or Type 1
  • Age between 18-80 years
  • Chronic foot ulcer more than 6 weeks
  • No sufficient response to best standard care delivered for six weeks.
  • PAD up to Fontaine stage III or IV period
  • CLI with the ankle brachial index (index ankle-brachial, ABI) <0.7 and (or) the percutaneous oxygen partial pressure (oxygen tension transcutaneous, TcPO2) <30mmHg

排除标准

  • HbA1c >12%
  • Hemoglobin <10 mg/dl
  • Creatinine clearance rate <30ml/min
  • Systemic bacterial, viral infections (Mei Du, hepatitis, cytomegalovirus infection, HIV, B19 infection, herpes virus infection) and sepsis
  • Have accepted the treatment of stem cells or growth factors
  • Have a history of malignant disease
  • Pregnancy
  • Mental illness history
  • Abnormal coagulation function
  • Allergic reaction
  • Severe cardiac insufficiency (III-IV NYHA)
  • Using vasoactive substances

研究组 & 干预措施

Autologous Bone Marrow Stem Cell

Experimental

Mesenchymal stem cells derived from bone marrow infusion

干预措施: mesenchymal stem cells (Biological)

结局指标

主要结局

Area of diabetic foot ulcers

时间窗: 3 months

To determine the ability of MSC to facilitate and accelerate diabetic foot ulcers healing.

次要结局

  • Improvement of transcutaneous oxygen partial pressure (TcPO2)(3 months)
  • Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)(3 months)
  • Pain (Visual-Analog Scale)(3 months)
  • Walking distance (treadmill) if possible(3 months)

研究者

发起方
Jie Shen
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Jie Shen

doctor

The Third Affiliated Hospital of Southern Medical University

研究点 (1)

Loading locations...

相似试验